Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Go back to Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies| (NYSE: TAK) | Delayed: 17.24 +0.42 (2.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.82 | 52 Week High | $0.55 | |||
| Open | $17.30 | 52 Week Low | $0.55 | |||
| Day High | $17.36 | P/E | N/A | |||
| Day Low | $17.22 | EPS | $-0.20 | |||
| Volume | 3,266,530 | |||||
